SCHEMBL7456502

SCHEMBL7456502

CCOC(=O)c1ccnc(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JMJD6 Q6NYC1 6/20 0.55
HSD17B2 P37059 1/20 0.53
PIK3CA P42336 1/20 0.52
CA12 O43570 3/20 0.50
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
CA7 P43166 3/20 0.50
CA9 Q16790 3/20 0.50
CA14 Q9ULX7 3/20 0.50
KCNK3 O14649 1/20 0.49
KCNK9 Q9NPC2 1/20 0.49
GPR119 Q8TDV5 1/20 0.47
ESR1 P03372 1/20 0.46
ESR2 Q92731 1/20 0.46
KDM5A P29375 1/20 0.45
KDM5C P41229 1/20 0.45
KDM4C Q9H3R0 1/20 0.45
KDM5B Q9UGL1 1/20 0.45
LMNA P02545 1/20 0.45
CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3723629 0.89 JMJD6 (0.56) JMJD6HSD17B2PIK3CACA12CA1
SCHEMBL4090687 0.83 JMJD6 (0.51) JMJD6PIK3CACA12CA1CA2
SCHEMBL4410496 0.83 PIK3CA (0.52) JMJD6PIK3CACA12CA1CA2
SCHEMBL17761 0.83 KDM4E (0.61) JMJD6CA12CA1CA2CA7
SCHEMBL29587235 0.83 KDM4E (0.61) JMJD6CA12CA1CA2CA7
SCHEMBL29505420 0.82 MAOB (0.58) JMJD6PIK3CAKDM5AKDM4CKDM5B
SCHEMBL19510738 0.82 MAOB (0.58) JMJD6PIK3CAKDM5AKDM4CKDM5B
SCHEMBL31300311 0.82 JMJD6 (0.56) JMJD6HSD17B2PIK3CACA12CA1
SCHEMBL188125 0.82 JMJD6 (0.56) JMJD6HSD17B2PIK3CACA12CA1
SCHEMBL4087566 0.82 JMJD6 (0.50) JMJD6HSD17B2PIK3CACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2834238-B1 DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS PFIZER (US) 2017-02-01 EP disclosed
US-6362336-B1 ADMINISTERING A QUINAZOLINE DERIVATIVE TO A WARM-BLOODED ANIMAL FOR PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT ZENECA LIMITED (GB) 2002-03-26 US disclosed
US-20020032208-A1 Chemical compounds ZENECA LIMITED 2002-03-14 US disclosed
EP-0873319-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2001-07-25 EP disclosed
US-6258951-B1 ANTICANCER, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 2001-07-10 US disclosed
US-6071921-A Chemical compounds ZENECA LIMITED (GB) 2000-06-06 US disclosed
US-5962458-A ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS ZENECA LIMITED (GB) 1999-10-05 US disclosed
EP-0873319-A1 QUINAZOLINE DERIVATIVES ZENECA LIMITED (GB) 1998-10-28 EP disclosed
WO-1997022596-A1 QUINAZOLINE DERIVATIVES ZENECA LIMITED (GB) 1997-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032208-A1 Chemical compounds FLT1, CNKSR1, KDR JMJD6 2207/4885HSD17B2 884/4885PIK3CA 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.